Hanall Biopharma Operating Profit Grows; Q3 Profit Expands Despite Lower Sales
Predicted impact: Low
Q3 operating profit of about ₩1.3B is small in absolute terms and was already reported in the window.
Hanall Biopharma한올바이오파마
009420 · KOSPI · ₩009420 · 한올바이오파마
₩37,500▼ ₩300 (0.79%)End-of-day · Oct 30, 2026 · End-of-day prices.
[BioS] Hanall Biopharma 3Q revenue ₩39.9B, "down 2.2% YoY"
Predicted impact: Low
Q3 revenue ₩39.9B, down 2.2%; results were already reported via preliminary earnings.
Hanall Biopharma Q3 Operating Profit at ₩1.3B, Up 265%
Predicted impact: Low
Q3 profit up 265% but only about ₩1.3B; the preliminary earnings were already reported.
한올바이오파마 바토클리맙 중국 품목허가 획득
Predicted impact: Low
Chinese approval for a partner's drug; small revenue impact relative to company size.
Hanall Biopharma's Technology-Exported Drug 'Batoclimab' Approved in China
Predicted impact: Low
Drug approval in China already reported in recent items; no new size disclosed.
Hanall Biopharma's Chinese Partner Obtains Approval for Myasthenia Gravis Drug
Predicted impact: Low
Same drug approval already reported in the same group of items, partner-level news.
Hanall Biopharma's Batoclimab Approved in China as New Drug for Myasthenia Gravis
Predicted impact: Low
Chinese approval of a partner's drug; no revenue size given and affects a small slice of sales.
Also known as: Hanall Biopharma / 한올바이오파마 / 009420 / KRX:009420
Source: KRX statistical information